Arcturus Therapeutics Shares Rise on Plans to Work with Thermo Fisher Scientific on Cystic Fibrosis Drug
By Kelly Cloonan
Shares of Arcturus Therapeutics gained after the company said it would work with Thermo Fisher Scientific to advance a therapy for cystic fibrosis.
The stock rose 5.8% to $7.29 in premarket trading Thursday. Shares had risen 12% year to date at Wednesday's market close.
The collaboration focuses on the Phase 3 development and potential commercialization of ARCT-032, Arcturus' investigational mRNA therapy for cystic fibrosis.
Under the agreement, Thermo Fisher will provide Phase 3 manufacturing, clinical research and related services to accelerate the development of ARCT-032, while Arcturus continues to advance the program.
Thermo Fisher will also receive exclusive commercial manufacturing rights to the drug under a separate commercial agreement, subject to regulatory approval of the treatment, Arcturus said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
July 02, 2026 08:08 ET (12:08 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States